RESUMEN
Proton-pump inhibitors (PPI), e.g., omeprazole or pantoprazole, are the most widely used drugs for various gastrointestinal diseases. However, more and more side effects, especially an increased risk of infections, have been reported in recent years. The underlying mechanism has still not yet been fully uncovered. Hence, in this study, we analyzed the T cell response after treatment with pantoprazole in vitro. Pantoprazole preincubation reduced the production and secretion of interferon (IFN)-γ and interleukin (IL)-2 after the T cells were activated with phytohemagglutinin (PHA)-L or toxic shock syndrome toxin-1 (TSST-1). Moreover, a lower zinc concentration in the cytoplasm and a higher concentration in the lysosomes were observed in the pantoprazole-treated group compared to the untreated group. We also tested the expression of the zinc transporter Zrt- and Irt-like protein (Zip)8, which is located in the lysosomal membrane and plays a key role in regulating intracellular zinc distribution after T cell activation. Pantoprazole reduced the expression of Zip8. Furthermore, we measured the expression of cAMP-responsive element modulator (CREM) α, which directly suppresses the expression of IL-2, and the expression of the phosphorylated cAMP response element-binding protein (pCREB), which can promote the expression of IFN-γ. The expression of CREMα was dramatically increased, and different isoforms appeared, whereas the expression of pCREB was downregulated after the T cells were treated with pantoprazole. In conclusion, pantoprazole downregulates IFN-γ and IL-2 expression by regulating the expression of Zip8 and pCREB or CREMα, respectively.
Asunto(s)
Interleucina-2 , Inhibidores de la Bomba de Protones , Inhibidores de la Bomba de Protones/farmacología , Pantoprazol/farmacología , 2-Piridinilmetilsulfinilbencimidazoles/farmacología , Zinc/farmacología , Linfocitos T , ÁcidosRESUMEN
INTRODUCTION: Proton pump inhibitors (PPIs) block the gastric H/K-ATPase, therefore inhibiting acid gastric secretion, leading to an increased pH (>4). They account for an extremely high number of prescriptions worldwide. Numerous drug-drug interactions have been described with PPIs, but all the described interactions do not have clinical significance. AREAS COVERED: This review will discuss the latest updates on drug-drug interactions with PPIs, focusing on the last 10-year publications in the following areas: anti-infective agents, anticancer drugs, antiplatelet agents and anticoagulants, and antidiabetics. EXPERT OPINION: Although pharmacokinetic interactions of PPIs have been described with many drugs, their clinical relevance remains controversial. However, given the extremely high number of people being treated with PPIs, clinicians should remain vigilant for interactions that may be clinically significant and require dose adjustment or therapeutic monitoring. Interestingly, not all PPIs have the same pharmacokinetic and pharmacodynamic profile, with some having a strong potential to inhibit CYP2C19, such as omeprazole, esomeprazole, and lansoprazole, while others, pantoprazole, rabeprazole, and dexlansoprazole, are weak CYP2C19 inhibitors. These may be preferred depending on co-prescribed treatments.In addition, new formulations have been developed to prevent some of the gastric pH-dependent drug interactions and should be evaluated in further large-scale prospective comparative studies.
Asunto(s)
Omeprazol , Inhibidores de la Bomba de Protones , 2-Piridinilmetilsulfinilbencimidazoles/farmacología , Interacciones Farmacológicas , Inhibidores Enzimáticos/farmacología , Inhibidores Enzimáticos/uso terapéutico , Esomeprazol/farmacología , Humanos , Omeprazol/farmacocinética , Estudios Prospectivos , Inhibidores de la Bomba de Protones/farmacocinéticaRESUMEN
At present, little information on the biopharmaceutical behaviour of proton pump inhibitors (PPIs) describing their absorption and biodistribution in vivo has been reported because the extreme instability of PPIs in the gastrointestinal environment makes it difficult to analyze such behaviour. In this work, a modified rat in situ intestinal perfusion model was employed to investigate absorption in the gastrointestinal tract and subsequent biodistribution of several PPIs (ilaprazole, esomeprazole and rabeprazole), which have different physicochemical properties. Our data indicated that PPIs exhibited significantly enhanced absorption rates in the whole intestine, including the duodenum, jejunum, ileum and colon, corresponding to the increase in the oil-water partition coefficient (LogP). PPIs and corresponding salt types showed no obvious differences in absorption, implying that solubility changes in the PPI have little effect on its absorption in the gastrointestinal tract. Among these PPIs, ilaprazole presented a more stable intestinal absorption behaviour, as well as more distribution and longer residence time in the stomach by HPLC-MS/MS analysis and radioactivity counts after 14C radiolabelling. These results may be useful information for PPI optimization and oral formulation design.
Asunto(s)
Absorción Fisicoquímica/efectos de los fármacos , Absorción Intestinal/efectos de los fármacos , Inhibidores de la Bomba de Protones/farmacología , 2-Piridinilmetilsulfinilbencimidazoles/farmacología , Absorción Fisicoquímica/fisiología , Adsorción , Animales , Productos Biológicos/farmacocinética , Productos Biológicos/farmacología , Fenómenos Químicos/efectos de los fármacos , China , Esomeprazol/farmacología , Femenino , Íleon/metabolismo , Absorción Intestinal/fisiología , Yeyuno/metabolismo , Masculino , Inhibidores de la Bomba de Protones/metabolismo , Inhibidores de la Bomba de Protones/farmacocinética , Rabeprazol/farmacología , Ratas , Ratas Sprague-Dawley , Espectrometría de Masas en Tándem/métodos , Distribución Tisular/efectos de los fármacosRESUMEN
OBJECTIVE: The aim: Of the work was to determine the content of pro- and anti-inflammatory cytokines in the blood serum of the control group rats and after 28 days of inhibiting HCl secretion in the stomach by proton pump blockers "Omeprazole" and "Pantoprazole". PATIENTS AND METHODS: Materials and methods: The studies were performed on 30 white non-linear male rats weighing 160-180 g, divided into three groups with 10 animals in each. The control (group 1) were injected intraperitoneally with water for injections within 28 days once a day. Group 2 was administered omeprazole. Group 3 was administered pantoprazole. The concentration of cytokines in the blood serum of rats was determined by the enzyme immunoassay method. For statistic data processing, Student's t-criterion for independent samples was applied. RESULTS: Results: After prolonged administration of omeprazole and pantoprazole, the blood serum concentrations of IFNγ, TNFα, IL-1 in rats increased by 58.5% and 3.41%, 73.3% and 48.4%, 80.2% and 40.8%, respectively, and IL-12B 40p decreased by 36.6% when using omeprazole and was almost indistinguishable from the control values when pantoprazole was administered. With administration of omeprazole, IL-4 concentration decreased by 39.8% and that of pantoprazole increased by 3.86% compared to the control. Administration of omeprazole and pantoprazole did not affect IL-6 concentration. CONCLUSION: Conclusion: Inhibition of hydrochloric acid secretion in the stomach of rats for 28 days using omeprazole and pantoprazole led to an imbalance between pro- and anti-inflammatory cytokines. The adverse effect of pantoprazole was less pronounced than that of omeprazole.
Asunto(s)
Inhibidores de la Bomba de Protones , Suero , 2-Piridinilmetilsulfinilbencimidazoles/farmacología , Animales , Bencimidazoles , Citocinas , Masculino , Inhibidores de la Bomba de Protones/farmacología , SulfóxidosRESUMEN
Epstein-Barr virus (EBV) is a ubiquitous herpesvirus responsible for several diseases, including cancers of lymphoid and epithelial cells. EBV cancers typically exhibit viral latency; however, the production and release of EBV through its lytic phase are essential for cancer development. Antiviral agents that specifically target EBV production do not currently exist. Previously, we reported that the proton pump inhibitor tenatoprazole, which blocks the interaction of ubiquitin with the ESCRT-1 factor Tsg101, inhibits production of several enveloped viruses, including EBV. Here, we show that three structurally distinct prazoles impair mature particle formation postreactivation and identify the impact on stages of replication. The prazoles did not impair expression of lytic genes representative of the different kinetic classes but interfered with capsid maturation in the nucleus as well as virion transport from the nucleus. Replacement of endogenous Tsg101 with a mutant Tsg101 refractory to prazole-mediated inhibition rescued EBV release. These findings directly implicate Tsg101 in EBV nuclear egress and identify prazoles as potential therapeutic candidates for conditions that rely on EBV replication, such as chronic active EBV infection and posttransplant lymphoproliferative disorders. IMPORTANCE Production of virions is necessary for the ubiquitous Epstein-Barr virus (EBV) to persist in humans and can set the stage for development of EBV cancers in at-risk individuals. In our attempts to identify inhibitors of the EBV lytic phase, we previously found that a prazole proton pump inhibitor, known to block the interaction of ubiquitin with the ESCRT-1 factor Tsg101, blocks production of EBV. We now find that three structurally distinct prazoles impair maturation of EBV capsids and virion transport from the nucleus and, by interfering with Tsg101, prevent EBV release from lytically active cells. Our findings not only implicate Tsg101 in EBV production but also identify widely used prazoles as candidates to prevent development of posttransplant EBV lymphomas.
Asunto(s)
2-Piridinilmetilsulfinilbencimidazoles/farmacología , Antivirales/farmacología , Proteínas de Unión al ADN/metabolismo , Complejos de Clasificación Endosomal Requeridos para el Transporte/metabolismo , Rabeprazol/farmacología , Factores de Transcripción/metabolismo , Liberación del Virus/efectos de los fármacos , Células A549 , Línea Celular Tumoral , Infecciones por Virus de Epstein-Barr/prevención & control , Células HEK293 , Herpesvirus Humano 4/efectos de los fármacos , Herpesvirus Humano 4/crecimiento & desarrollo , Humanos , Inhibidores de la Bomba de Protones/farmacología , Carga Viral/efectos de los fármacos , Activación Viral/efectos de los fármacos , Latencia del Virus/efectos de los fármacos , Replicación Viral/efectos de los fármacosRESUMEN
Ilaprazole is a proton pump inhibitor used to treat digestive diseases. In this study, blood samples were collected after oral administration of ilaprazole and prepared by liquid-liquid extraction. The metabolites of ilaprazole were detected by liquid chromatography-high-resolution mass spectrometry (LC-HRMS) and LC-MSn. A total of twelve in vivo metabolites were detected in rat plasma and six new metabolites of ilaprazole, including one reductive metabolite with sulfide (M3), two hydroxylated metabolites with sulfoxide (M7 and M8), and three oxidative metabolites with sulfone (M9, M11, and M12), were identified. The possible metabolic pathways of ilaprazole and the fragmentation behaviors of its metabolites were elucidated. The result of the in silico prediction indicates that all the new metabolites showed the potential ability to inhibit H+/K+-ATPase activity.
Asunto(s)
2-Piridinilmetilsulfinilbencimidazoles , ATPasa Intercambiadora de Hidrógeno-Potásio , Plasma/metabolismo , Inhibidores de la Bomba de Protones , 2-Piridinilmetilsulfinilbencimidazoles/farmacocinética , 2-Piridinilmetilsulfinilbencimidazoles/farmacología , Administración Oral , Animales , Cromatografía Líquida de Alta Presión , Masculino , Inhibidores de la Bomba de Protones/farmacocinética , Inhibidores de la Bomba de Protones/farmacología , Ratas , Ratas Sprague-Dawley , Espectrometría de Masa por Ionización de ElectrosprayRESUMEN
A ligand-based virtual screening study to search for giardicidal compounds on a 6551 ChEMBL drugs database was carried out using molecular similarity. Three fingerprints implemented in MayaChemTools with different design and validated by ROC curves, were used. Twelve compounds were retrieved from this screening, from which, four representative compounds were selected to carry out biological assays. Whereas two compounds were commercially available, the additional two compounds were synthesized during the development of this work. The biological assays revealed that the compounds possess in vitro activity against five strains of Giardia intestinalis, each with different susceptibility/resistance rates to metronidazole, albendazole and nitazoxanide. Particularly, tenatoprazole showed the best effect against the WB and IMSS strains. Furthermore, fabomotizole, tenatoprazole and ipriflavone showed a higher activity against resistant strains than the reference drugs: metronidazole, albendazole and nitazoxanide.
Asunto(s)
2-Piridinilmetilsulfinilbencimidazoles/uso terapéutico , Antiprotozoarios/uso terapéutico , Bencimidazoles/uso terapéutico , Carbamatos/uso terapéutico , Isoflavonas/uso terapéutico , 2-Piridinilmetilsulfinilbencimidazoles/farmacología , Antiprotozoarios/farmacología , Bencimidazoles/farmacología , Carbamatos/farmacología , Humanos , Técnicas In Vitro , Isoflavonas/farmacología , LigandosRESUMEN
BACKGROUND: The effects of PPIs on human sperm fertilizing capacity were poorly investigated although these drugs are widely over-used. Two publications retrospectively studied relationships between any PPI intake and sperm parameters from patients consulting at infertility clinics, but the conclusions of these reports were contradictory. Only two reports investigated the effects of lansoprazole and omeprazole on sperm motility and found lansoprazole to be deleterious and omeprazole to be neutral for sperm motility. The inconsistency of the PPI effect in the previous reports emphasizes the need for more basic research on human spermatozoa, taking into account the hypothesis that the different PPI drugs may have different effects on sperm physiology. OBJECTIVES: Do PPIs, which are among the most widely sold drug in the word, impact negatively human sperm capacitation and sperm motility? MATERIALS AND METHODS: The effects of PPIs on human sperm maturation and motility were analyzed by CASA, flow cytometry, and Western blot. RESULTS: We tested the impact of 6 different PPIs on human sperm motility and capacitation. We showed that pantoprazole, but not the other PPIs, decreased sperm progressive motility and capacitation-induced sperm hyperactivation. We therefore investigated further the effects of pantoprazole on sperm capacitation, and we observed that it had a significant deleterious effect on the capacitation-induced hyperpolarization of the membrane potential and capacitation-associated protein phosphorylation. DISCUSSION AND CONCLUSION: Our results indicate that exposure to pantoprazole has an adverse effect on the physiological competence of human spermatozoa. As the capacitation process takes place within the female tract, our results suggest that PPIs intake by the female partner may impair in vivo sperm maturation and possibly fertilization. Moreover, the absence of adverse effect by PPIs on mouse sperm emphasizes the need to develop reprotox assays using human material to better assess the effects of medication intake on sperm physiology.
Asunto(s)
Pantoprazol/efectos adversos , Inhibidores de la Bomba de Protones/efectos adversos , Análisis de Semen/métodos , Capacitación Espermática/efectos de los fármacos , Motilidad Espermática/efectos de los fármacos , 2-Piridinilmetilsulfinilbencimidazoles/efectos adversos , 2-Piridinilmetilsulfinilbencimidazoles/farmacología , Adulto , Fertilización/efectos de los fármacos , Humanos , Lansoprazol/efectos adversos , Lansoprazol/farmacología , Masculino , Potenciales de la Membrana/efectos de los fármacos , Persona de Mediana Edad , Omeprazol/efectos adversos , Omeprazol/farmacología , Pantoprazol/farmacología , Fosforilación/efectos de los fármacos , Inhibidores de la Bomba de Protones/farmacología , Rabeprazol/efectos adversos , Rabeprazol/farmacología , Estudios Retrospectivos , Maduración del Esperma/fisiología , Espermatozoides/fisiología , Adulto JovenRESUMEN
Two proton pump inhibitors, tenatoprazole and esomeprazole, were previously shown to inhibit HIV-1 egress by blocking the interaction between Tsg101, a member of the ESCRT-I complex, and ubiquitin. Here, we deepen our understanding of prazole budding inhibition by studying a range of viruses in the presence of tenatoprazole. Furthermore, we investigate the relationship between the chemistry of prodrug activation and HIV-1 inhibition for diverse prazoles currently on the market. We report that tenatoprazole is capable of inhibiting the replication of members of the enveloped filo, alpha, and herpes virus families but not the flavivirus group and not the non-enveloped poliovirus. Another key finding is that prazole prodrugs must be activated inside the cell, while their rate of activation in vitro correlated to their efficacy in cells. Our study lays the groundwork for future efforts to repurpose prazole-based compounds as antivirals that are both broad-spectrum and selective in nature.
Asunto(s)
2-Piridinilmetilsulfinilbencimidazoles/farmacología , VIH-1/fisiología , Inhibidores de la Bomba de Protones/farmacología , Replicación Viral/efectos de los fármacos , Células HeLa , HumanosRESUMEN
Proton pump inhibitors (PPIs) are used widely for the treatment of acid-related disorders. Despite their excellent efficacy and tolerance, the pharmacodynamics and pharmacokinetics of PPIs are affected by each patient's CYP2C19 and gastric H+,K+-ATPase genotype. The aim of this review was to analyze the effect of genetic polymorphisms on the pharmacodynamic and pharmacokinetic properties of PPIs. The gastric acid-suppressive effect of PPIs is affected by both gastric H+,K+-ATPase and CYP2C19 polymorphisms, although gastric H+,K+-ATPase polymorphisms may have larger effects. Ilaprazole and rabeprazole show relatively small differences in the pharmacokinetic and pharmacodynamic properties and clinical efficacy among the different CYP2C19 genotypes. Compared with oral administration, the intravenous infusion of PPIs is less affected by CYP2C19 polymorphism. At the same dose, each enantiomer has less variation among different CYP2C19 genotypes than a racemate mixture.
Asunto(s)
2-Piridinilmetilsulfinilbencimidazoles/farmacología , 2-Piridinilmetilsulfinilbencimidazoles/farmacocinética , Inhibidores de la Bomba de Protones/farmacología , Inhibidores de la Bomba de Protones/farmacocinética , Humanos , Variantes FarmacogenómicasRESUMEN
BACKGROUND AND AIMS: Proton pump inhibitors (PPIs) are effective antagonists of gastric acid secretion used to treat a number of gastro-esophageal disorders. The present study investigated the effect of Pantoprazole on vascular relaxation in-vitro and ex-vivo and its effect on blood coagulation in an animal model. MAIN METHODS: Isolated mouse arterial rings were pre-contracted in-vitro with phenylephrine and concentration-response curves to the acetylcholine relaxing effect were constructed in the presence of escalating concentrations of pantoprazole. In another set of experiments, male albino mice weighing â¼25â¯g were administered a daily dose of pantoprazole (0.4â¯mg by oral gavage) for four consecutive weeks; a vehicle control group was run in parallel. At the end of the treatment period, thoracic aorta was isolated for the assessment of vascular function ex-vivo. Blood samples were also collected to evaluate the effect of chronic pantoprazole therapy on coagulation parameters, namely, prothrombin time (PT) and activated partial thromboplastin time (aPTT). KEY FINDINGS: Vascular responsiveness to acetylcholine demonstrated a reduced relaxation of the arterial ring from baseline in the presence of different concentrations of pantoprazole (1⯵M: 54.69⯱â¯1.42%, 10⯵M: 34.64⯱â¯0.90% and 100⯵M: 31.50⯱â¯0.67% vs. control 74.39⯱â¯1.426%, pâ¯<â¯0.001). Furthermore, acetylcholine-induced relaxation of the aorta was significantly diminished after four weeks of administrating pantoprazole to mice (37.12⯱â¯2.50%) compared with the control group (72.47⯱â¯1.68%, pâ¯<â¯0.001). This, however, wasn't accompanied by significant changes in the phenylephrine-induced vasoconstriction. Animals that received pantoprazole daily for four weeks also exhibited increased blood coagulation time in comparison to the vehicle control group (PT 45.30⯱â¯3.52â¯s vs. 15.30⯱â¯0.70â¯s, pâ¯<â¯0.05; aPTT 96.1⯱â¯4.62â¯s vs. 48⯱â¯1.97â¯s, pâ¯<â¯0.05, respectively). SIGNIFICANCE: The results of the present investigation suggest that pantoprazole reduces arterial relaxation and interferes with blood coagulation. Additional studies are warranted to assess the clinical implications of such observations.
Asunto(s)
2-Piridinilmetilsulfinilbencimidazoles/farmacología , Coagulación Sanguínea/efectos de los fármacos , Vasodilatación/efectos de los fármacos , Vasodilatadores/farmacología , Acetilcolina/farmacología , Animales , Aorta/efectos de los fármacos , Modelos Animales de Enfermedad , Masculino , Ratones , Ratones Endogámicos BALB C , Pantoprazol , Tiempo de Tromboplastina Parcial/métodos , Fenilefrina/farmacologíaRESUMEN
OBJECTIVE: Introduction: The pathogenesis of gastroesophageal reflux disease (GERD) is a topical issue of modern gastroenterology. There are a number of scientific papers on changes in the qualitative and quantitative composition of saliva, which triggers a cascade of biochemical reactions, the consequence of which is the destruction of the resistance of the mucous membrane of the esophagus. Calcium is a macro element that provides the normal functioning of cells. Parathormone also regulates the metabolism of calcium in the body. The aim: To study the level of calcium of saliva in patients with GERD before and after 6 months after treatment, to investigate the correlation with the concentration of parathyroid hormone. PATIENTS AND METHODS: Materials and methods: The samples of saliva of patients with GERD before and after treatment are analyzed. The content of calcium in saliva was determined by photometric method. To test the level of parathyroid hormone, the Intact-PTH ELISA test was used. The treatment was carried out with pantoprazole doses of 40 mg per day. Normal values of electrolyte levels in human saliva are set on 10 virtually healthy volunteers. Data processing was carried out using Microsoft Excel. Correlations were calculated using the Pearson method. RESULTS: Results: 25 samples of saliva have been analyzed: 15 patients with GERD and 10 healthy individuals. Concentration of parathormonone in plasma was consistent with normal values. The concentration of calcium saliva for practically healthy individuals was 2.48 ± 0.07 mmol / L, in patients with GERD before treatment 1.92 ± 0.16 mmol / L, after treatment 2.04 ± 0.07 mmol / L. The correlation coefficient between the level of calcium salivation in patients with GERD and the plasma parathyroid hormone concentration before treatment was 0.21, after treatment 0.73. CONCLUSION: Conclusions: The concentration of calcium is statistically significantly reduced in patients with GERD by 22.5% and increased by 10% after treatment. There is a high correlation between the concentration of calcium after treatment and the level of plasma parathyroid hormone.
Asunto(s)
Calcio de la Dieta/análisis , Reflujo Gastroesofágico/metabolismo , Hormona Paratiroidea/sangre , Saliva/química , 2-Piridinilmetilsulfinilbencimidazoles/farmacología , 2-Piridinilmetilsulfinilbencimidazoles/uso terapéutico , Calcio de la Dieta/metabolismo , Femenino , Reflujo Gastroesofágico/tratamiento farmacológico , Humanos , Masculino , Pantoprazol , Hormona Paratiroidea/metabolismoRESUMEN
To estimate the clinical impact of pharmacokinetic modulation via breast cancer resistance protein (BCRP), in vivo approaches in nonclinical settings are desired in drug development. Clinical observation has identified curcumin as a promising candidate for in vivo selective BCRP inhibition, in addition to several well known inhibitors, such as lapatinib and pantoprazole. This study aimed to confirm the inhibitory efficacy of curcumin on gastrointestinal BCRP function in cynomolgus monkeys and to perform comparisons with lapatinib and pantoprazole. Oral area under the plasma concentration-time curve (AUC) and bioavailability of well known BCRP (sulfasalazine and rosuvastatin), P-glycoprotein (fexofenadine, aliskiren, and talinolol), and CYP3A (midazolam) substrates were investigated in the presence and absence of inhibitors. Oral exposures of sulfasalazine and rosuvastatin were markedly elevated by curcumin with minimal changes in systemic clearance, whereas pharmacokinetic alterations after fexofenadine, aliskiren, and talinolol oral exposure were limited. Curcumin increased oral midazolam exposure without affecting systemic clearance, presumably owing to partial inhibition of intestinal CYP3A. Lapatinib increased the oral AUC for sulfasalazine to a greater extent than curcumin did, whereas pantoprazole had a smaller effect. However, lapatinib also exerted significant effects on fexofenadine, failed to selectively discriminate between BCRP and P-glycoprotein inhibition, and had an effect on oral midazolam exposure comparable with that of curcumin. Thus, pharmacokinetic evaluation in monkeys demonstrated that pretreatment with curcumin as an in vivo selective BCRP inhibitor was more appropriate than pretreatment with lapatinib and pantoprazole for the assessment of the impact of BCRP on gastrointestinal absorption in nonrodent models.
Asunto(s)
Transportador de Casetes de Unión a ATP, Subfamilia G, Miembro 2/metabolismo , Neoplasias de la Mama/tratamiento farmacológico , Curcumina/farmacología , Proteínas de Neoplasias/metabolismo , 2-Piridinilmetilsulfinilbencimidazoles/farmacología , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Animales , Disponibilidad Biológica , Neoplasias de la Mama/metabolismo , Células CACO-2 , Línea Celular Tumoral , Curcumina/farmacocinética , Citocromo P-450 CYP3A/metabolismo , Femenino , Humanos , Absorción Intestinal/efectos de los fármacos , Mucosa Intestinal/metabolismo , Intestinos/efectos de los fármacos , Lapatinib , Macaca fascicularis , Masculino , Midazolam/farmacología , Pantoprazol , Quinazolinas/farmacología , Rosuvastatina Cálcica/farmacología , Sulfasalazina/farmacología , Terfenadina/análogos & derivados , Terfenadina/farmacologíaRESUMEN
PURPOSE: The objective of this study was to evaluate the safety, pharmacokinetics, and pharmacodynamics of S-(-)-pantoprazole (PPZ) sodium injections following single and multiple intravenous doses in healthy Chinese subjects. METHODS: The dosage groups were set as followed: 20 mg of single and multiple intravenous administration of S-(-)-PPZ, 40 mg of single and multiple intravenous administration of S-(-)-PPZ or pantoprazole, and 80 mg of single dosage group of S-(-)-PPZ. Subjects were sampled for pharmacokinetic analysis and were monitored for 24-h intragastric pH prior to and 48-h intragastric pH after administration for the pharmacodynamic study. The pharmacokinetic and pharmacodynamic parameters were compared between S-(-)-PPZ and PPZ. Safety was evaluated on the basis of adverse events, vital signs, laboratory tests, and physical examination. RESULTS: All adverse events were mild and of limited duration. Maximum plasma concentration and area under the concentration-time curve for S-(-)-PPZ were dose proportional over the range of 20-80 mg following a single intravenous administration. Elimination rate constant and half-life observed statistical difference from a single dose to multiple doses in 40 mg of S-(-)-PPZ groups. After administration of a single dose, the mean 24-h intragastric pH value was observed higher in 80-mg group than in 40- and 20-mg groups. Slightly increase of intragastric pH was found after a single dose of 40 mg S-(-)-PPZ than 40 mg PPZ; however, the differences were not statistically significant. CONCLUSIONS: Twice daily of 40 mg S-(-)-PPZ sodium injections is effective in achieving satisfying acid inhibition. Compared with plasma R-(+)-PPZ levels, most subjects presented more potent and prolonged suppression of gastric acid of S-(-)-PPZ, while a few subjects showed faster metabolic rate of S-(-)-PPZ in vivo.
Asunto(s)
2-Piridinilmetilsulfinilbencimidazoles/efectos adversos , Antiulcerosos/efectos adversos , Ácido Gástrico/metabolismo , Mucosa Gástrica/efectos de los fármacos , Inhibidores de la Bomba de Protones/efectos adversos , 2-Piridinilmetilsulfinilbencimidazoles/administración & dosificación , 2-Piridinilmetilsulfinilbencimidazoles/farmacocinética , 2-Piridinilmetilsulfinilbencimidazoles/farmacología , Adulto , Antiulcerosos/administración & dosificación , Antiulcerosos/farmacocinética , Antiulcerosos/farmacología , Área Bajo la Curva , China , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Composición de Medicamentos , Femenino , Determinación de la Acidez Gástrica , Mucosa Gástrica/metabolismo , Semivida , Humanos , Inyecciones Intravenosas , Masculino , Tasa de Depuración Metabólica , Monitoreo Ambulatorio , Pantoprazol , Inhibidores de la Bomba de Protones/administración & dosificación , Inhibidores de la Bomba de Protones/farmacocinética , Inhibidores de la Bomba de Protones/farmacología , Reproducibilidad de los Resultados , Estereoisomerismo , Adulto JovenRESUMEN
PURPOSE: Metabolic surgery alters the secretion of gastrointestinal hormones that influence glycemic control. Elevated gastrin has been suggested to benefit patients with type 2 diabetes and has been reported following sleeve gastrectomy in rats. The present study compares the effect of hypergastrinemia following sleeve gastrectomy with proton-pump inhibitor therapy on glycemic control and beta-cell mass in lean, diabetic animals. METHODS: Thirty-three diabetic Goto-Kakizaki rats were randomized into pantoprazole + sham operation (GK-PPI), sleeve gastrectomy (GK-SG) and vehicle + sham operation (GK-V). Body weight, glucose parameters, HbA1c, glucagon-like peptide 1, gastrin, insulin and lipids were evaluated for eighteen postoperative weeks. Total beta-cell mass was quantified by optical projection tomography. RESULTS: After surgery, body weight development was equal among groups (P g = 0.75). Fasting and stimulated gastrin increased for GK-PPI and GK-SG vs. GK-V (p < 0.05 for all). Fasting blood glucose was decreased for GK-PPI and GK-SG vs. GK-V (p < 0.05 and p = 0.052). HbA1c was lower for GK-SG vs. GK-V at 6 weeks and for GK-PPI vs. GK-V at twelve- and eighteen weeks postoperative (p < 0.05 for all); a borderline difference was observed for GK-SG vs. GK-V at 18 weeks (p = 0.054). Total- and LDL cholesterol was elevated for GK-PPI compared to the other two groups (p < 0.05 for all). Beta-cell mass did not differ among groups (p = 0.35). CONCLUSIONS: Hypergastrinemia following sleeve gastrectomy and pantoprazole has a similar, modest effect on glycemic control in Goto-Kakizaki rats but does not enhance beta-cell mass after 18 weeks. Hypergastrinemia in the setting of T2DM might be of clinical relevance.
Asunto(s)
2-Piridinilmetilsulfinilbencimidazoles/farmacología , Diabetes Mellitus Experimental/terapia , Diabetes Mellitus Tipo 2/terapia , Gastrectomía/métodos , Gastrinas/farmacología , Células Secretoras de Insulina/patología , Animales , Terapia Combinada , Diabetes Mellitus Experimental/patología , Diabetes Mellitus Tipo 2/patología , Hormonas/farmacología , Células Secretoras de Insulina/efectos de los fármacos , Masculino , Pantoprazol , RatasRESUMEN
HIV-1 replication requires Tsg101, a component of cellular endosomal sorting complex required for transport (ESCRT) machinery. Tsg101 possesses an ubiquitin (Ub) E2 variant (UEV) domain with a pocket that can bind PT/SAP motifs and another pocket that can bind Ub. The PTAP motif in the viral structural precursor polyprotein, Gag, allows the recruitment of Tsg101 and other ESCRTs to virus assembly sites where they mediate budding. It is not known how or even whether the UEV Ub binding function contributes to virus production. Here, we report that disruption of UEV Ub binding by commonly used drugs arrests assembly at an early step distinct from the late stage involving PTAP binding disruption. NMR reveals that the drugs form a covalent adduct near the Ub-binding pocket leading to the disruption of Ub, but not PTAP binding. We conclude that the Ub-binding pocket has a chaperone function involved in bud initiation.
Asunto(s)
Proteínas de Unión al ADN/metabolismo , Complejos de Clasificación Endosomal Requeridos para el Transporte/metabolismo , VIH-1/metabolismo , Factores de Transcripción/metabolismo , Ensamble de Virus/fisiología , Liberación del Virus/fisiología , Productos del Gen gag del Virus de la Inmunodeficiencia Humana/metabolismo , 2-Piridinilmetilsulfinilbencimidazoles/farmacología , Fármacos Anti-VIH/farmacología , Sitios de Unión , Línea Celular Tumoral , Proteínas de Unión al ADN/genética , Complejos de Clasificación Endosomal Requeridos para el Transporte/genética , Esomeprazol/farmacología , Células HEK293 , Células HeLa , Humanos , Chaperonas Moleculares/metabolismo , Unión Proteica , Dominios Proteicos , Factores de Transcripción/genética , Ubiquitina/metabolismo , Ensamble de Virus/efectos de los fármacos , Ensamble de Virus/genética , Liberación del Virus/efectos de los fármacos , Liberación del Virus/genéticaRESUMEN
OBJECTIVES: Pantoprazole is a proton pump inhibitor that has been shown to inhibit bone resorption. The aim of the study was to investigate whether pantoprazole can prevent development of botulinum toxin (BTX)-induced disuse osteopenia in mice. METHODS: Forty-eight 16-week-old female C57BL/6J mice were randomized into 4 groups (n=12): Base, Ctrl, BTX, and BTX+Pan. The Base group was euthanized at study start. The BTX and BTX+Pan groups were immobilized by injections with BTX in one hind limb. The BTX+Pan group was injected i.p. daily with 100 mg pantoprazole per kg bodyweight. The mice were euthanized after 3 weeks of treatment. The skeletal status was investigated by DEXA, µCT, mechanical testing, dynamic bone histomorphometry, and RT-qPCR. The bone sites investigated were tibia, femur, L5 vertebra, and humerus. RESULTS: Injections of BTX induced a pronounced and significant loss of bone density, microstructure, and strength in the immobilized hind limb. Furthermore, the localized intramuscular injections of BTX lead to a slight loss of bone and bone strength at the L5 vertebra and humerus. Treatment with pantoprazole did not have any bone protective or deleterious effects. CONCLUSION: Pantoprazole was unable to prevent the development of BTX induced disuse osteopenia in skeletally mature female C57BL/6J mice.
Asunto(s)
2-Piridinilmetilsulfinilbencimidazoles/farmacología , Enfermedades Óseas Metabólicas/prevención & control , Huesos/efectos de los fármacos , Inhibidores de la Bomba de Protones/farmacología , Animales , Densidad Ósea/efectos de los fármacos , Enfermedades Óseas Metabólicas/inducido químicamente , Toxinas Botulínicas/toxicidad , Femenino , Ratones , Ratones Endogámicos C57BL , Neurotoxinas/toxicidad , Pantoprazol , Distribución AleatoriaRESUMEN
Treatment of retinoblastoma -a pediatric cancer of the developing retina- might benefit from strategies to inhibit the blood-retinal barrier (BRB). The potent anticancer agent topotecan is a substrate of efflux transporters BCRP and P-gp, which are expressed at the BRB to restrict vitreous and retinal distribution of xenobiotics. In this work we have studied vitreous and retinal distribution, tumor accumulation and antitumor activity of topotecan, using pantoprazole as inhibitor of BCRP and P-gp. We used rabbit and mouse eyes as BRB models and patient-derived xenografts as retinoblastoma models. To validate the rabbit BRB model we stained BCRP and P-gp in the retinal vessels. Using intravitreous microdialysis we showed that the penetration of the rabbit vitreous by lactone topotecan increased significantly upon concomitant administration of pantoprazole (P=0.0285). Pantoprazole also increased topotecan penetration of the mouse vitreous, measured as the vitreous-to-plasma topotecan concentration ratio at the steady state (P=0.0246). Pantoprazole increased topotecan antitumor efficacy and intracellular penetration in retinoblastoma in vitro, but did not enhance intratumor drug distribution and survival in mice bearing the intraocular human tumor HSJD-RBT-2. Anatomical differences with the clinical setting likely limited our in vivo study, since xenografts were poorly vascularized masses that loaded most of the vitreous compartment. We conclude that pharmacological modulation of the BRB is feasible, enhances anticancer drug distribution into the vitreous and might have clinical implications in retinoblastoma. CHEMICAL COMPOUNDS INCLUDED IN THIS MANUSCRIPT: Topotecan (PubChem CID: 60700) Pantoprazole sodium (PubChem CID: 15008962).
Asunto(s)
2-Piridinilmetilsulfinilbencimidazoles/farmacología , Barrera Hematorretinal/efectos de los fármacos , Neoplasias de la Retina/tratamiento farmacológico , Retinoblastoma/tratamiento farmacológico , Inhibidores de Topoisomerasa I/uso terapéutico , Topotecan/uso terapéutico , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/antagonistas & inhibidores , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/genética , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Transportador de Casetes de Unión a ATP, Subfamilia G, Miembro 2/antagonistas & inhibidores , Transportador de Casetes de Unión a ATP, Subfamilia G, Miembro 2/genética , Transportador de Casetes de Unión a ATP, Subfamilia G, Miembro 2/metabolismo , Animales , Barrera Hematorretinal/metabolismo , Humanos , Ratones Desnudos , Pantoprazol , Conejos , Neoplasias de la Retina/genética , Neoplasias de la Retina/metabolismo , Retinoblastoma/genética , Retinoblastoma/metabolismo , Inhibidores de Topoisomerasa I/farmacocinética , Topotecan/farmacocinética , Cuerpo Vítreo/metabolismo , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
Use of agents to suppress gastric acid secretion is common among patients with hepatitis C virus (HCV) infection. The aims of this open-label, three-period, fixed-sequence study were to evaluate the effect of famotidine and pantoprazole on the pharmacokinetics and safety of elbasvir/grazoprevir fixed-dose combination (FDC) in 16 healthy subjects. Elbasvir and grazoprevir each exhibited similar pharmacokinetics following single-dose administration of elbasvir/grazoprevir with or without famotidine or pantoprazole. Geometric mean ratios (GMRs) of grazoprevir AUC(0,∞), Cmax , and C24 (elbasvir/grazoprevir + famotidine or elbasvir/grazoprevir + pantoprazole vs. elbasvir/grazoprevir) ranged from 0.89-1.17. Similarly, GMRs of elbasvir AUC(0,∞), Cmax , and C24 (elbasvir/grazoprevir + famotidine or elbasvir/grazoprevir + pantoprazole vs. elbasvir/grazoprevir) ranged from 1.02-1.11. These results indicate that gastric acid-reducing agents do not modify the pharmacokinetics of elbasvir or grazoprevir in a clinically relevant manner and may be coadministered with elbasvir/grazoprevir in HCV-infected patients without restriction.
Asunto(s)
2-Piridinilmetilsulfinilbencimidazoles/farmacocinética , Antivirales/farmacocinética , Benzofuranos/farmacocinética , Famotidina/farmacocinética , Hepacivirus/efectos de los fármacos , Imidazoles/farmacocinética , Quinoxalinas/farmacocinética , 2-Piridinilmetilsulfinilbencimidazoles/efectos adversos , 2-Piridinilmetilsulfinilbencimidazoles/farmacología , Adulto , Amidas , Antivirales/efectos adversos , Antivirales/farmacología , Benzofuranos/efectos adversos , Benzofuranos/sangre , Benzofuranos/farmacología , Carbamatos , Ciclopropanos , Demografía , Interacciones Farmacológicas , Famotidina/efectos adversos , Famotidina/farmacología , Femenino , Humanos , Imidazoles/efectos adversos , Imidazoles/sangre , Imidazoles/farmacología , Masculino , Persona de Mediana Edad , Pantoprazol , Quinoxalinas/efectos adversos , Quinoxalinas/sangre , Quinoxalinas/farmacología , Sulfonamidas , Factores de Tiempo , Adulto JovenRESUMEN
OBJECTIVE: Cancer cachexia is often present in patients with advanced malignant tumors, and the subsequent body weight reduction results in poor quality of life. However, there has been no progress in developing effective clinical therapeutic strategies for skeletal muscle wasting in cancer cachexia. Herein, we explored the functions of pantoprazole on cancer cachexia skeletal muscle wasting. METHODS: The mouse colon adenocarcinoma cell line C26 was inoculated in the right forelimb of male BALB/C mice to establish a cancer cachexia model. The animals were treated with or without different concentrations of pantoprazole orally, and the body weight, tumor growth, spontaneous activity, and muscle functions were determined at various time points. Two weeks later, the levels of serum IL-6 and TNF-α, the mRNA levels of gastrocnemius JAK2 and STAT3, and the expression levels of p-JAK2, p-STAT3, Fbx32, and MuRF1 were examined with ELISA assay, qRT-PCR assay, and Western blotting, respectively. Further studies were performed to assess the levels of Fbx32 and MuRF1 expression and morphological changes. RESULTS: Pantoprazole can alleviate cancer cachexia-induced body weight reduction and inhibit skeletal muscle wasting in a dose-dependent manner. Our results indicated that pantoprazole treatment can decrease the levels of serum IL-6 and TNF-α (56.3% and 67.6%, respectively), and inhibit the activation of the JAK2/STAT3 signaling pathway. Moreover, the expression levels of MuRF1 and Fbx32 were also suppressed after pantoprazole treatment. CONCLUSION: Our findings suggested that pantoprazole can alleviate cancer cachexia skeletal muscle wasting by inhibiting the inflammatory response and blocking the JAK2/STAT3 or ubiquitin proteasome pathway.